Replies to post #58646 on DNAprint Genomics (DNAG)

[johnnyfiber]

W2play, I have read your posts for many years and have respected and appreciated them. I've seen you go round and round with the clown.

DNAG aside, (not to mention that DNAG came on board with Emory the moment the EPA for MK0518 became public, or the fact that in that 24 week period to date in Feb. "miraculous strides were made in the development of that compound) a cure for HIV has been found by Merck, at Emory:

In fact, most patients who had been treated on a variety of antiretroviral therapies who were given MK0518 - being developed by Merck - were able to suppress their bloodstream levels of virus to undetectable levels.

http://www.medpagetoday.com/InfectiousDisease/2006CROIMeeting/tb/2644

This is huge.

Can anybody on this board tell me if our technology participated in this? Can anybody tell me what other applications our technology at Emory could have been applied to?

Does anybody realize Wall Street has heard about this and is just waiting for validation to invest heavily in personalized medicine?

http://www.thestreet.com/markets/corrections/10337044.html

For the record, I own 1,377,222 shares of DNAG. Should I sell them and buy MRK?

[bag8ger]

Worktoplay,

"johnnyfiber...Let me add something to this mix. Frog has spent years fighting windmills, attempting to create the impression that DNAPrint's science is somehow second rate. Yet in the face of his twisted arguments stands the ever growing number of highly respected scientists working collaboratively with DNAPrint."

Not only collaboratively but at DNAG as employees, highly respected PHD's who apparently don't read froggie's reams of discouragement.

As they say at FOX news, when you find yourself in a hole, froggie, keep digging.

[frogdreaming]

work to P, Allow me a rebuttal. LOL

Frog has spent years fighting windmills, attempting to create the impression that DNAPrint's science is somehow second rate. Yet in the face of his twisted arguments stands the ever growing number of highly respected scientists working collaboratively with DNAPrint.

My friend, let us not forget your own contributions over the years. While I have attempted to have discussions about the actual science and intellectual property (mostly in vain), you have argued that there is no need to concern ourselves with science, we merely have to see what famous names may have, in fact, spoken to our scientists. One can only assume that you consider rubbing elbows with legitimate scientists and organizations is an equitable substitute for actually accomplishing anything.

When do you suppose they will turn their attention from embellishing their rolodex's and actually turn out a product?

I seem to remember you waxing ecstatic over those great scientists at NYU a half a decade ago and the legitimacy thus conferred on our little enterprise. Given your optimistic reviews, what is your impression of when that long ago venture will bear fruit?

Once you have established a prediction then maybe we can interpolate a date when we can expect results from this latest 'rubbing of elbows' with legitimate persons. lol

Do you think that at some time they will be able to take their acquired ligitimacy to Ebay and get some return for it? Nothing else seems to have any shot at near term income.

regards,
frog

[johnnyfiber]

w2play, It's realy what it's all about. It is the worth of the company.

PII-39
DETERMINATION OF RESPONSE TO TAXOL/CARBOPLATIN
IN OVARIAN CANCER PATIENTS. T. N. Frudakis, PhD, M.
Thomas, PhD, Z. Gaskin, BS, H. J. Gomez, MD, PhD, DNAPrint
genomics Inc., Sarasota, FL.
BACKGROUND: We deal with genetic complexity through population structure to reduce the number of markers,condition case/control study results and combat the confounding influence of genetic heterogeneity and minor locus effects. This abstract describes the screening of patient genomes to construct a DNA based test for measuring Taxol/Carboplatin response proclivities.
METHODS: Pan genome maps of Ancestry Informative Markers
to estimate individual biogeographical ancestry admixture for patient samples, integrated with a case/control design were used to screen the genome.
RESULTS: Taxol/Carboplatin response was associated with Haplotypes
in 3 xenobiotic metabolism genes and a few other SNPs.
Integrating ancestry and gene-specific features enabled construction of a classification method for predicting Taxol/Carboplatin response proclivities that is capable of relatively sensitive, specific and powerful
performance in “blind” sample classification trials.
CONCLUSIONS: When gene haplotype and SNP associations
are viewed through the lens of biogeographical ancestry admixture, pattern emerges that enables relatively accurate classification of patient
response proclivities to Taxol/Carboplatin in ovarian cancer
patients.

When gene haplotype and SNP associations
are viewed through the lens of biogeographical ancestry admixture, pattern emerges that enables relatively accurate classification of patient


http://www.ascpt.org/annualmeeting2007/meetingabstracts05.pdf

Mark Bouzyk, PhD
Director, Center for Medical Genomics, Emory University

Dr Bouzyk is the new director of the Center for Medical Genomics (CMG). The CMG is a core facility that provides state of the art laboratory capabilities to enable high throughput genetic linkage and association studies ranging from candidate gene to genomic screens all supported by a robust and flexible data management infrastructure. Dr Bouzyk has come to Emory with more than eight years track record in a global pharmaceutical company, GlaxoSmithKline, where one of his roles was to serve as Director of Genetic Laboratory Sciences leading the company’s high throughput genotyping efforts in Europe.

I believe it notable that a man of his obvious credentials would provide this quote in DNAPrint's PR announcing the collaboration:

"This technology will be very useful for population stratification, and will serve as an extremely important quality control, particularly for large scale case control genetic association studies. Additionally, it will provide benefits in other areas, including pharmacogenetics,"said Dr. Mark Bouzyk, Director of Emory's Center for Medical Genomics.